Cognos Therapeutics files Form D for $2 million debt offering
The Inglewood, California biotechnology company reported $250,000 sold toward the offering as of a July 2, 2026 signature date, though the filing lists zero investors.
Cognos Therapeutics Inc, based in Inglewood, California, filed a Form D notice with the Securities and Exchange Commission disclosing a new exempt securities offering. The filing is a new notice with a date of first sale of 2026-05-21.1
The offering covers debt securities as well as a security to be acquired upon exercise of an option, warrant, or other right to acquire a security.1 The company claimed the Rule 506(b) exemption under Regulation D.1
The total offering amount is listed as $2,000,000, with $250,000 sold and $1,750,000 remaining to be sold.1 The minimum investment accepted from any outside investor is $10,000.1
Despite the $250,000 already sold, the filing states that the total number of investors who have already invested in the offering is 0.1 This is an internal inconsistency within the document itself, as it is unclear how proceeds could be collected without any recorded investors.
The company reported $0 in both sales commissions and finders' fees, listed as estimates.1 Proceeds directed to executive officers, directors, or promoters named in the filing were also reported as $0, estimated.1
The related persons named in the filing are Frank Adell, Thomas Chen, and Eli Gang, all listed with roles as directors, with Adell also identified as an executive officer.1 The Form D was signed by Frank Adell, identified as CEO, with a signature date of 2026-07-02.1 The company indicated it does not intend the offering to last more than one year.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.